Omicron News and Research

RSS

FDA approves second COVID-19 booster dose for older and immunocompromised individuals

Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

29 Mar 2022

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

A recent viewpoint illustrated that evaluating T cell responses to COVID-19 is essential to inform public health initiatives.

29 Mar 2022

Study explores the waning efficacy of SARS-CoV-2 ChAdOx1 and BNT162b2 vaccines

A new study evaluated the waning efficacy of the COVID-19 ChAdOx1 and BNT162b2 vaccines over six months following the second dose.

29 Mar 2022

Study tracks the rapid shift from Omicron BA.1 to BA.2 sub-variant dominance in Sweden

Researchers tracked the rapid shift from the new SARS-CoV-2 VOC Omicron BA.1 sub-variant dominance to BA.2 sub-variant dominance in Sweden between January and March 2022.

29 Mar 2022

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Researchers evaluated the cellular and humoral immunity following heterologous and homologous COVID-19 immunization regimens for up to five months.

29 Mar 2022

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

In a new study, researchers tested the bi-, tri-, and tetravalent formulations of Newcastle disease virus (NDV)-based low-cost vaccine in mice.

29 Mar 2022

New compound delivered in a nasal spray effectively treats delta variant infection in mice

Researchers have shown a new compound delivered in a nasal spray is highly effective in preventing and treating COVID-19 caused by the Delta variant in mice.

29 Mar 2022

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Researchers determine whether there was any reduction in the death rate in elderly COVID-19 patients following the second booster dose.

28 Mar 2022

Natural SARS-CoV-2 antibodies persist for six months in children

Researchers investigate the presence of antibodies against SARS-CoV-2 in children between the ages of five and 19 after infection.

28 Mar 2022

Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

Researchers analyze the effect of prior infection, vaccination, and hybrid immunity against SARS-CoV-2 BA.1 and BA.2 Omicron subvariant infections.

28 Mar 2022

COVID-19 vaccination continues to protect adults against severe illness and death

COVID-19 vaccination continues to help protect adults against severe illness with COVID-19, including hospitalizations and death, according to two reports released in today's MMWR.

28 Mar 2022

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Researchers evaluated the neurological complications due to SARS-CoV-2 D614G strain, and variants of concern, Delta and Omicron in a hamster model.

28 Mar 2022

Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

A new study assessed the dynamics of viral load of SARS-CoV-2 Omicron and Delta variants of concern post-vaccination and previous infection.

28 Mar 2022

Study estimates protection against reinfection following primary SARS-CoV-2 infection

A recent study investigated the protection provided by the primary SARS-CoV-2 infection against reinfection.

28 Mar 2022

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

A recent study investigated the disease severity of SARS-CoV-2 Omicron BA.2 infection among Hong Kong children.

28 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

Clinical determinants of post-COVID-19 thromboembolism

Researchers quantify the risk of acute VTE due to SARS-CoV-2 infection in ambulatory settings.

27 Mar 2022

Omicron News and Research

FDA approves second COVID-19 booster dose for older and immunocompromised individuals

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

Study explores the waning efficacy of SARS-CoV-2 ChAdOx1 and BNT162b2 vaccines

Study tracks the rapid shift from Omicron BA.1 to BA.2 sub-variant dominance in Sweden

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

New compound delivered in a nasal spray effectively treats delta variant infection in mice

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Natural SARS-CoV-2 antibodies persist for six months in children

Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

COVID-19 vaccination continues to protect adults against severe illness and death

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

Study estimates protection against reinfection following primary SARS-CoV-2 infection

Benefits of heterotypic vaccination against variants of SARS-CoV-2

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Severe outcomes in hospitalized children during the Omicron BA.2-dominated fifth wave in Hong Kong

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

Clinical determinants of post-COVID-19 thromboembolism

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News